http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-794798-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc948de7402f67df396f8d16f5425bcc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-46 |
| filingDate | 1956-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1958-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-794798-A |
| titleOfInvention | Pharmaceutical compositions |
| abstract | A non-toxic effervescent pharmaceutical composition comprises a solid organic acid material such as tartaric, citric or succinic acid or their potassium or sodium acid salts and a material such as sodium bicarbonate or carbonate which reacts with the organic acid material on contact with moisture to form a gas and a surface-active agent. The surface-active agent may be cationic, anionic, or nonionic. In the first case it should preferably amount by weight to not more than 0.2 per cent of the composition; in the second, not more than 2 per cent; in the third, not more than 25 per cent. A mixture of cationic and nonionic or anionic and nonionic surface-active agents may be used. The pH of the dissolved composition in water should be from 2 to 10 and preferably 3 to 7. Specified surface-active agents are (a) cationic: coconut alkyl dimethylbenzyl ammonium chloride, cetyl trimethyl ammonium chloride, dodecyl dimethylallyl ammonium chloride, cetyl dimethylbenzyl ammonium chloride; (b) anionic: sodium lauryl sulphate, sodium hepta-decyl sulphate; (c) nonionic: the polyethylene glycol mono ester of ricinoleic acid or lauric acid, lauryl ether of polyalkoxyethanol, p-diisobutyl or p-triisopropyl phenoxypolyethoxyethanol having approximately 9 to 11 ethoxy groups. Therapeutic agents may be added for their specific effect: specified are propylparahydroxybenzoate, oxyquinoline sulphate, procaine hydrochloride, butethamine formate and hydrochloride, sulphacetamide, p-nitrosulphathiazole, bacitracin, aureomycin hydrochloride, potassium penicillin. Diluents such as starch and sucrose may be added and the composition may be tabletted. Many examples are given. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-1179335-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2035119-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105997924-A |
| priorityDate | 1955-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 83.